BeOne Medicines (ONC) Current Deferred Revenue (2015 - 2023)

BeOne Medicines (ONC) has 8 years of Current Deferred Revenue data on file, last reported at $159.0 million in Q2 2023.

• Quarterly Current Deferred Revenue fell 2.67% year-over-year to $159.0 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $159.0 million (down 2.67% YoY) and the FY2022 annual result came in at $213.9 million, down 28.71% from the prior year.
• Current Deferred Revenue eased to $159.0 million in Q2 2023 per ONC's latest filing, from $185.5 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $300.0 million in Q4 2021 and bottomed at $17.5 million in Q1 2019.
• The 4-year median for Current Deferred Revenue is $159.0 million (2023), against an average of $141.4 million.
• Peak annual rise in Current Deferred Revenue reached 156.89% in 2022, while the deepest fall reached 28.71% in 2022.
• Tracing ONC's Current Deferred Revenue over 4 years: stood at $17.5 million in 2019, then soared by 1613.89% to $300.0 million in 2021, then retreated by 28.71% to $213.9 million in 2022, then declined by 25.64% to $159.0 million in 2023.
• Per Business Quant, the three latest ONC Current Deferred Revenue figures stand at $159.0 million (Q2 2023), $185.5 million (Q1 2023), and $213.9 million (Q4 2022).

Peer Comparison